| Cyclophosphamide-induced disruption of umami taste functions and taste epithelium N Mukherjee, ER Delay Neuroscience 192, 732-745, 2011 | 50 | 2011 |
| MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells N Mukherjee, J Skees, KJ Todd, DA West, KA Lambert, WA Robinson, ... Cell death & disease 11 (6), 443, 2020 | 49 | 2020 |
| Alternative treatments for melanoma: targeting BCL-2 family members to de-bulk and kill cancer stem cells N Mukherjee, JV Schwan, M Fujita, DA Norris, YG Shellman Journal of Investigative Dermatology 135 (9), 2155-2161, 2015 | 46 | 2015 |
| Pre-treatment with amifostine protects against cyclophosphamide-induced disruption of taste in mice N Mukherjee, BL Carroll, JL Spees, ER Delay PloS one 8 (4), e61607, 2013 | 42 | 2013 |
| Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells N Mukherjee, SN Reuland, Y Lu, Y Luo, K Lambert, M Fujita, ... Journal of Investigative Dermatology 135 (3), 842-850, 2015 | 40 | 2015 |
| Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells N Mukherjee, Y Lu, A Almeida, K Lambert, CW Shiau, JC Su, Y Luo, ... Oncotarget 8 (29), 46801, 2017 | 37 | 2017 |
| Cellular mechanisms of cyclophosphamide-induced taste loss in mice N Mukherjee, S Pal Choudhuri, RJ Delay, ER Delay PloS one 12 (9), e0185473, 2017 | 31 | 2017 |
| BH3 mimetics induce apoptosis independent of DRP-1 in melanoma N Mukherjee, A Strosnider, B Vagher, KA Lambert, S Slaven, ... Cell death & disease 9 (9), 907, 2018 | 27 | 2018 |
| Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments N Mukherjee, A Almeida, KA Partyka, Y Lu, JV Schwan, K Lambert, ... Oncotarget 7 (51), 84594, 2016 | 26 | 2016 |
| Simultaneously inhibiting BCL2 and MCL1 is a therapeutic option for patients with advanced melanoma N Mukherjee, CM Amato, J Skees, KJ Todd, KA Lambert, WA Robinson, ... Cancers 12 (8), 2182, 2020 | 25 | 2020 |
| Correction: pre-treatment with amifostine protects against cyclophosphamide-induced disruption of taste in mice N Mukherjee, BL Carroll, JL Spees, ER Delay PLoS One 8 (7), 2013 | 10 | 2013 |
| Enrichment of melanoma stem-like cells via sphere assays N Mukherjee, KA Lambert, DA Norris, YG Shellman Melanoma: Methods and Protocols, 185-199, 2021 | 9 | 2021 |
| Continued evolution of H5Nx avian influenza viruses in Bangladeshi live poultry markets: Pathogenic potential in poultry and mammalian models R El-Shesheny, J Franks, J Turner, P Seiler, D Walker, K Friedman, ... Journal of virology 94 (23), 10.1128/jvi. 01141-20, 2020 | 8 | 2020 |
| Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy R Popovic, F Dunbar, C Lu, K Robinson, D Quarless, SE Warder, ... American Journal of Hematology 97 (2), E47, 2022 | 7 | 2022 |
| Expression differences in BCL2 family members between uveal and cutaneous melanomas account for varying sensitivity to BH3 mimetics N Mukherjee, CR Dart, CM Amato, A Honig-Frand, JR Lambert, ... Journal of Investigative Dermatology 142 (7), 1912-1922. e7, 2022 | 5 | 2022 |
| S146: venetoclax in patients with chronic lymphocytic leukemia with 17P deletion: 6-year follow-up and genomic analyses in a pivotal phase 2 trial S Stilgenbauer, E Tausch, AW Roberts, MS Davids, B Eichhorst, M Hallek, ... HemaSphere 6, 47-48, 2022 | 4 | 2022 |
| A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine CR Dart, N Mukherjee, CM Amato, A Goulding, M MacBeth, R Van Gulick, ... Pharmaceuticals 14 (8), 749, 2021 | 2 | 2021 |
| SASH1 interacts with TNKS2 and promotes human melanocyte stem cell maintenance KA Lambert, CM Clements, N Mukherjee, TR Pacheco, SX Shellman, ... bioRxiv, 2023.09. 26.559624, 2023 | 1 | 2023 |
| MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade N Mukherjee, E Katsnelson, TM Brunetti, K Michel, KL Couts, KA Lambert, ... Cell Death & Disease 15 (3), 198, 2024 | | 2024 |
| Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study M Herling, C Dearden, F Zaja, D El-Sharkawi, W Ding, M Bellido, A Khot, ... Blood Advances, 2024 | | 2024 |
